Accordingly, both nonprofit funders and biotechnology companies currently are investing in infrastructure for association studies. Elements of that emerging infrastructure such as prospective cohorts and biobanks are being developed with participants from a limited number of populations with the goal of applying their findings to many other populations. However, not all phenotypes and populations may be as suitable for this approach as others. Which populations and phenotypes will benefit and which will not in the coming era of large-scale association studies?
BACKGROUND
The International HapMap Project, at US $120 million perhaps the most high-profile example of infrastructure investment in the next generation of genetic research, is intended to provide a set of markers to facilitate costeffective association studies. To that end, the HapMap is using samples from four populations (Yoruba in Ibadan, Nigeria; Japanese in Tokyo, Japan; Han Chinese in Beijing, China; and Utah residents with ancestry from Northern and Western Europe known as the CEPH samples) to construct a genomic resource that will identify the common (45%) haplotypes that are estimated as structuring 80-85% of all genetic variation among humans. 3, 4 Preliminary research suggests that the same three to five common haplotypes will be found at any given chromosomal region in most if not all human populations, although in different frequencies. 5 A haplotype is a linear sequence of bases on the same chromosome (usually varying in length from 100 to 100 000 bases) that is identifiable as one of a number of alternative structures for a given segment of that chromosome (by virtue of there being different single-nucleotide polymorphisms for some bases within that segment). As such, nearby alleles in the same haplotype are inherited together more often than is expected by chance, a phenomenon that is called 'linkage disequilibrium'. Owing to that coinheritance, haplotypes offer a way of summarizing the genetic variation found within them. Researchers need identify only a few SNPs (called 'tag SNPs') to identify the longer haplotype, which greatly decreases genotyping costs for gene discovery. 6 Those tag SNPs can be used to look for patterns or similarities in interindividual genetic variation among those affected by a disease or drug response when compared with unaffected controls (ie an association study). The rationale for this strategy is that those similarities (most of which will not contribute to the drug response or disease in question) will allow researchers to narrow the possible chromosomal regions in which a contributing gene may be located. 7, 8 Tag SNPs can be tested for their association with a drug response or an increased susceptibility to a disease, with the idea that the actual contributing gene(s) will be located nearby the associated marker(s). Other techniques, such as positional cloning, then can be used to identify the gene or genes in question.
To have sufficient power to detect weak-to-intermediate genetic effects, association studies will require very large numbers of DNA samples linked with phenotypic information. In addition to traditional case-control or cross-sectional samples, those data increasingly will come either from prospective cohorts or from biobanks (which often include both retrospective and prospective data), the establishment and maintenance of which also will require significant funding and effort. The advantage of biobanks and prospective cohorts over casecontrol designs is that the former provide longitudinal data for multiple phenotypes.
The questions about the overall association study strategy, though, are, first, the extent to which 'common' markers or patterns of variation discovered in a few (albeit carefully chosen) populations will be useful for gene discovery in other populations and, second, the applicability of gene discoveries in a given population to other populations. Positive answers to both these questions often have been linked because it makes no sense to construct a HapMap without large biobanks and prospective cohorts in which to use tag SNPs. At the same time, large biobanks and cohorts are best utilized for association studies, the cost of which can become prohibitive without markers like tag SNPs that can reduce the number of bases that must be genotyped.
The debate that has developed around these two questions has focused on the applicability of what has been called the Common Disease/ Common Variant (or CD/CV) hypothesis, 9 which supports the view that one or a few genetic contributors account for significant numbers of cases of many common, complex diseases in most or all populations 10, 11 The CD/CV hypothesis, though, is not unique to disease expression and can be extended to other phenotypes such as drug response.
Several critiques, however, have been made of the CD/CV strategy underlying the infrastructure being developed around association studies. First, some have argued that common variants may be the exception rather than the rule, and that most common diseases and drug responses may have multiple, rare (o1% frequency) genetic contributors that likely vary considerably by population. [12] [13] [14] Second, the effects of some common variants may be relatively weak such that even association studies with very large numbers of participants will not have sufficient power to detect them. 15 Third, the tag SNPs identified by the HapMap Project may not be applicable to other populations (due in part to the effects of local selection pressures and genetic drift that have affected haplotype frequencies since the populations sampled for the HapMap Project diverged from one another), requiring that different tag SNPs be developed for each population or sample studied. 16, 17 These critiques will be neither generally proven nor disproved. Rather, they will apply to some populations, some phenotypes, and some genomic regions but not to all. Such factors as the effect size of a disease susceptibility or drug response locus, the frequency of the disease or drug response allele(s), the frequency of the marker allele(s), and the extent of linkage disequilibrium between the marker and the disease susceptibility or drug response locus will figure into a formula that can indicate the likelihood of success for an association study for a specific phenotype in a particular population with a given study design. 15 We can, though, consider potential scenarios in which tag SNPs and disease susceptibility and drugresponse variants discovered using prospective cohorts and biobanks in some populations may be useful in other populations. These scenarios more fully describe the range of logical possibilities of which the CD/ CV hypothesis is but one. It is useful to consider that fuller range to think more systematically about the ways in which investments in the infrastructure to support association studies (and investigators' and funders' future choices increasingly to rely on those studies) may result in disparities in the benefits of genetic research.
SCENARIOS
Scenarios in which genetic discoveries in one population may benefit other populations are best understood against the framework of human population history. The human population as a whole is relatively young, with migrations out of Africa to other continents beginning approximately 100 000 years ago. Consequently, common patterns of variation and common variants that arose in Africa prior to the continental diaspora still constitute a shared catalogue or map that is the ancestral basis for contemporary population-specific patterns of sequence variation. Subsequent mutation and recombination events have added to those original variants, although the greater allelic diversity continues to be found in ancestral African populations. Founder effects among those who migrated out of Africa decreased the allelic diversity in non-African populations, while subsequent population bottlenecks also tended to reduce diversity. Nevertheless, genetic drift can increase the frequency of otherwise rare genetic patterns and variants, particularly when those already exist in the population.
In contrast, locally varying selection pressures have been more responsible for differences in frequencies of allelic variants, with selection against a trait tending to increase rare alleles and positive selection increasing the frequency of adaptive alleles, while similar environmental conditions across populations have tended to promote selection of alleles in similar frequencies. Selection sometimes also can affect the frequency of patterns of variation, such as when an ancestral haplotype is nearby an allele on which there is a positive or negative selective pressure.
Indeed, the continued sorting and resorting of individuals over time into loosely bounded, transitory groupings (ie populations) each of which has experienced somewhat unique, dynamically varying selection and demographic events has resulted in the different scenarios for contemporary populations described below.
Common Phenotype, Common pattern, Common Variant (CCC)
This is what usually is meant by the CD/CV hypothesis. SNPs, haplotypes, and variant alleles that are common across contemporary populations most likely emerged from the original range of human variation prior to the continental diaspora. In addition, it may be the case that some recombination subsequent to the continental diaspora has tended to occur at the same chromosomal 'hotspots' such that many independent changes in haplotype structure are nonetheless congruent. 18 Those common patterns (whether the result of ancestral haplotypes or hotspot recombination) can be identified in one population or set of populations and used in gene discovery in other populations. Moreover, common disease susceptibility or drug response variants discovered in one population will benefit all populations (to the extent that they are present in varying frequencies in other groups). Mutations in APOE that increase risks for Alzheimer disease and heart disease often are cited as an example of common variants present in populations throughout the world. 9 In fact, although relatively few variants that contribute to common diseases have been confirmed to date, most of the variants that are known are common across populations (see Table 1 ). Other common variants with weak effects will require very large numbers of association study participants to be detected. In some cases, that larger number may become prohibitive such that a family linkage study or candidate gene approach is a more practical approach.
Common Phenotype, Common Pattern, Rare Variant (CCR) In cases in which more than one gene or allele may contribute to susceptibility for the same disease or to response to the same drug and in which those alleles occur in different frequencies across populations, contributing genes and alleles found in one population may not necessarily be the more common contributors for those diseases or drug responses in other populations. Otherwise rare variants can become more frequent in some populations due to a variety of selection pressures and demographic circumstances, often in combination with one another. 19 Nonetheless, patterns of genetic variation that are common across populations can be used to discover otherwise rare variants that are specific to or more frequent in particular populations where the common pattern is in association with the rare variant in those populations at a similar frequency. 15 Patterns of genetic variation such as haplotypes, SNPs, or regions of linkage disequilibrium often are located on chromosomes nearby contributing variants but do not necessarily contain the variants such that it is possible for a population to have both common patterns of variation (the result largely of demographic events that are neutral with respect to selection) and higher frequencies of some otherwise rare variants (which may result either from positive selection or demographic circumstances or both). Where a variant is rare in all populations, of course, an association study is unlikely to discover it and family linkage studies (which require fewer participants) are more appropriate.
Common Phenotype, Rare Pattern, Common Variant (CRC) Some populations (particularly relatively small groups in which genetic drift has affected frequencies) may have haplotypes, SNPs, or linkage disequilibrium regions that are more frequent among their members but rare in other populations. It has been suggested, for instance, that the common haplotypes identified by the HapMap Project may not apply to some chromosomal regions in Native American populations because those indigenous groups historically had relatively small effective populations sizes and were reproductively isolated for at least 10 000 years from populations sampled for the HapMap. 20 In those circumstances, otherwise rare patterns of variation could increase in frequency if they were nearby or included alleles under positive selection or were among the less diverse range of variation inherited after a founding or bottleneck event. 19 Consequently, populations that are most distantly related to the groups from which gene discovery resources such Hapmap were constructed and that have experienced local selection pressures or genetic drift (or both) may not necessarily benefit fully from markers such as tag SNPs derived from patterns of genomic variation common to other populations with different histories. However, due both to the shared African origin of all populations and to current members who have some ancestors from other populations, at least some of the patterns common to other populations still will be evident in some frequency in populations that have higher frequencies of otherwise rare patterns. Thus, populations with some unique patterns of variation still may benefit from the use of common patterns for gene discovery (although these may be less efficient in part because they are likely to occur at different frequencies than the disease and drug response alleles in question). While these populations will be less than ideal candidates for association studies, their members nonetheless will benefit from such studies that discover common variants in other populations.
Common Phenotype, Rare Pattern, Rare Variant (CRR) Of course, some populations with higher frequencies of otherwise rare patterns of genetic variation also will have higher frequencies of otherwise rare variants that contribute to some common diseases and drug responses. Such populations are likely to be strongly affected by relatively recent founder effects or bottlenecks (hence the otherwise rare patterns of variation), while the frequency of otherwise rare variants may be amplified by locally varying selection pressures in combination with the effects of demographic events. These populations are least likely to benefit from the discovery of genetic patterns and variants common in other populations, at least in the cases of those rare variants, and thus will benefit more from genetic Rare Phenotype, Common Pattern, Common Variant (RCC) Some diseases and drug responses are rare in most populations but occur at higher frequencies in a few populations. Where those otherwise rare phenotypes are more likely to occur, but are associated with patterns of genetic variation and candidate variants that are also common in other populations that have lower rates of phenotypic expression, it is likely that some environmental difference between populations is the more probable cause for the higher frequencies of the rare phenotypes. In those cases, a common pattern of variation can be used to indicate the need for more extensive environmental investigation in populations with higher rates of phenotypic expression.
Rare Phenotype, Common Pattern, Rare Variant (RCR)
In other cases, a common pattern of genetic variation may be used to identify an association with an otherwise rare variant that occurs at higher frequencies in the populations with higher rates of phenotypic expression. In other words, these are complex diseases or drug responses that have not yet become common in most populations, suggesting that a higher localized prevalence may be due to a relatively recent demographic event or to positive selective pressure for a reproductive enhancement also conferred by the variant, as in the case of heterozygosity for the sickle cell mutation. Ashkenazi, Hutterite, and Old Order Amish populations are examples in which a number of otherwise rare diseases occur more often due to higher frequencies of otherwise rare variants. 19 Still, while the variant may be rare in the populations used to develop the common patterns, this does not diminish the fact that genetic variation research in those other populations can be of benefit in discovering the rare variant in populations in which it and the phenotype to which it contributes are more frequent.
Rare Phenotype, Rare Pattern, Rare Variant (RRR) Populations that continue to be strongly affected by localized selective pressures and/or by recent population bottlenecks and founder effects may have higher frequencies of otherwise rare phenotypes, associated patterns of genetic variation, and genetic variants such that patterns of variation and genetic variants common to other populations are of relatively little benefit for disease susceptibility and drug response gene discovery. These constitute the ideal model of the 'isolated' population. Whether such populations exist, though, in the present context of multigenerational globalization is uncertain.
DISTRIBUTION OF BENEFITS
Of the seven scenarios outlined above, three (CCC, CCR, and RCR) describe situations in which populations will benefit directly from gene discovery resources such as the HapMap developed in other populations, two (CCC and CRC) describe situations in which populations will benefit directly from gene discoveries in other populations, two (CRR and RRR) describe situations in which there are likely to be few if any direct benefits either from gene discovery resources or from gene discoveries in other populations, and one (RCC) describes situations in which environmental contributors are more likely responsible than genetic contributors.
The scenarios suggest two, perhaps, competing principles of justice (at least insofar as funding resources are limited):
The first is that investments in association study infrastructure should maximize returns for the benefit of the most people. That principle would favor investments that take advantage of the CD/CV hypothesis (and its various corollaries detailed in scenarios CCC, CCR, RCR, and CRC) in studies of diseases and drug responses. Current trends in research infrastructure investment suggest that this principle is being applied through funding for resources such as HapMap and the formation of a growing number of large cohorts and biobanks. While the latter are not necessarily premised on the CD/CV hypothesis, justifications for projects such as the UK Biobank and NIH-sponsored prospective cohorts and business plans for projects such as deCODE (a for-profit venture making use of DNA samples and medical records from large numbers of Icelandic citizens) have emphasized the numbers of people affected by complex diseases such as cancer and the benefits that gene discoveries in one population will have for other populations. 21, 22 The second is that additional investments should be targeted for those populations that may not benefit from research in other populations because of higher frequencies of otherwise rare variants or rare patterns of variation (or both) among their members (ie CRR and RRR). It is unknown how many populations and diseases fit this profile, but it is probably a relatively small number. Moreover, because small effective population size, geographic isolation, founder effects, and bottlenecks are likely to have contributed to higher frequencies of otherwise rare patterns and variants among populations in this category, their current numbers may be too small to support association studies that often require significant numbers of participants with a particular phenotype, especially to detect weaker genetic effects. Thus, biobanks or cohorts formed in those populations should emphasize recruiting participants who are genealogically related to one another to take advantage of opportunities for family linkage studies.
Perhaps the greater disparity will be in the cases of conditions that affect large numbers of people worldwide, but for which there may be multiple, rare variants rather than one or a few common variants. Even in the presence of common patterns of variation, a number of population-specific studies will be required to identify these variants and their frequencies. However, improvements in the costs and efficiencies of gene resequencing and other emerging technologies may facilitate the discovery of multiple, rare variants where a candidate gene or biological mechanism already has been identified in another population.
That possibility suggests that the benefits of population-specific research into contributors to drug response and disease susceptibility are not limited only to the discovery of particular genetic variants. Some discoveries can lead to development of a drug or a biological insight that is of broad relevance, even if the genetic variants are more restricted in distribution. For example, familial hypercholesterolemia is a rare disease, but the discovery of the genetic variants underlying that condition led to our understanding of the function of the LDL receptor and cholesterol metabolism, 23 which in turn has led to the development of statins. Statins are broadly useful for a number of more common diseases, 24 even if the genetic variation that began the process of discovery is rare.
Other indirect consequences of genetic investigation, though, may not be as beneficial. Larger biobanks or cohorts will help identify or confirm environmental contributors that are more common among their members, but will be less likely to help identify those less common contributors that are rare among most study participants. Indeed, the additional power that a larger biobank or cohort provides to detect common effects simultaneously can mask those contributors that are primarily localized within subsets of the larger sample, depending on how participant information is collected and analyzed. In most cases, because it is expensive to investigate environmental exposure histories in great detail for large numbers of participants, 25 large biobanks or cohorts tend to collect participant information through closed-end questions-that is, by giving participants a range of predetermined answers and forcing them to choose among them-and by taking fewer, often less precise measurements of continuous traits. 26 The difficulty, though, is that such broad, decontextualized responses and streamlined data collection make it less likely that weak or localized effects will be detected.
CONCLUSIONS
We are at the beginning of a shift in genetic research from an historical focus on studying rare conditions that affect relatively few people (ie Mendelian traits) to giving more attention and resources to conditions that affect the many (ie common, complex traits). Previously, there would have been little point in evaluating funding for genetic studies based on numbers of people who are affected by a particular condition, by the size of the population being studied, or by the extent to which other populations are benefited; indeed, such criteria would have been detrimental to the development of knowledge and technology that was best nurtured in the context of rare, monogenic conditions. Now, though, we are at the point at which those criteria are becoming more relevant. Viewed in that historical light, the shift toward infrastructure investment in association studies that emphasize resources and discoveries common to multiple populations is a logical consequence of improvements both in our scientific knowledge of the genome and in technology.
Obviously, populations from which the association study infrastructure of biobanks, cohorts, and tag SNPs is being constructed-as well as others with close historical relationships to them-will experience the clearest, most immediate benefits from it. Nonetheless, based on these scenarios, the common patterns of variation identified by the HapMap and association studies that discover common patterns and variants in selected populations have considerable potential for benefiting other populations, including certain cases of rare diseases and drug responses in which common patterns of variation nonetheless may be useful in gene discovery (ie CCR and RCR). 20 Even populations with rare patterns of variation but with common phenotypes and common variants (ie CRC) will benefit from research conducted in other populations (because of the common variants), although they will not be ideal candidates for association studies using tag SNPs developed in other populations.
Despite the potential for widespread benefits, however, the emerging emphasis on genetic variation infrastructure and association studies could create some ongoing disparities in the benefits from genetic research. Of course, there are not sufficient resources to fund separate gene discovery resources such as HapMap or cohorts and biobanks in every population or for all possible diseases and drug responses. As resources continue to flow to the infrastructure needed to support association studies, provisions for those populations that are least likely to benefit from studies in other populations (ie CCR, CRR and RRR) should be considered.
We suggest the following priorities: For populations in which otherwise rare variants are more frequent, it will be important to make funding available to establish biobanks or cohorts so that association studies specific to those populations will be possible. For populations with otherwise rare patterns of variation, funding for more population-specific gene discovery resources (ie population-specific HapMaps) will be important, especially for use in studies of phenotypes that do not have common genetic contributors. For both relatively small populations (many of which will be economically disadvantaged) and for phenotypes and variants that are truly rare in all populations, continued funding for biobanks or cohorts enriched to support family linkage studies and other smallerscale kinds of approaches should be protected from competing directly with large-scale, more expensive (and more trendy) projects. For both common and rare variants with weak effects, developing smaller-scale alternatives to very large association studies may be a more cost-effective approach. Finally, we should be careful not to extrapolate the broad applicability of common patterns of genetic variation and common variants to research on environmental contributors to those same phenotypes, since the latter will tend to be much more variable both within and between populations.
